173 related articles for article (PubMed ID: 21654386)
1. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
Sawas A; Diefenbach C; O'Connor OA
Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
[TBL] [Abstract][Full Text] [Related]
2. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
5. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Delmonte A; Ghielmini M; Sessa C
Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
[TBL] [Abstract][Full Text] [Related]
7. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
Jahangiri S; Friedberg J; Barr P
Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
[TBL] [Abstract][Full Text] [Related]
8. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Rodgers TD; Reagan PM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies for B-cell non-Hodgkin lymphoma.
Briones J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
[TBL] [Abstract][Full Text] [Related]
10. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
12. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
13. New drugs and targeted treatments in Hodgkin's lymphoma.
Provencio M; Sánchez A; Sánchez-Beato M
Cancer Treat Rev; 2014 Apr; 40(3):457-64. PubMed ID: 24095205
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors in lymphoma.
Copeland A; Buglio D; Younes A
Curr Opin Oncol; 2010 Sep; 22(5):431-6. PubMed ID: 20683267
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
16. B-cell receptor pathobiology and targeting in NHL.
Macias-Perez IM; Flinn IW
Curr Oncol Rep; 2012 Oct; 14(5):411-8. PubMed ID: 22865093
[TBL] [Abstract][Full Text] [Related]
17. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
19. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.
Moskowitz CH
J Nucl Med; 1998 Aug; 39(8 Suppl):2S-10S. PubMed ID: 9708564
[TBL] [Abstract][Full Text] [Related]
20. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Mukherji D; Pettengell R
Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
